2017-11-17 08:01:23GRMN   - $60.75
0.46 (0.76%) , UNH - $211.13
1.27 (0.61%) … 08:0111/17/17 11/1708:01 11/17/1708:01 | Garmin announces integration with UnitedHealthcare Motion wellness programGarmin International (GMRN) announced the inclusion of the vivosmart 3 activity tracker1 as a buy-up option into the recently expanded UnitedHealthcare (UNH) Motion wellness program, powered by Qualcomm Life (QCOM). Offered to employers by UnitedHealthcare, a UnitedHealth Group company, UnitedHealthcare Motion is an employer-sponsored, wearable device wellness program that enables people using activity trackers, including the Garmin vivosmart 3, to monitor progress toward daily walking goals. Featuring an ultra-slim design, a hidden display, and helpful fitness and wellness monitoring tools, the vivosmart 3 has been helping users achieve their activity goals since its announcement in April 2017. "Garmin is excited to participate in an innovative program that seeks to improve health outcomes and reduce costs for employers and individuals," said Cliff Pemble, Garmin president and CEO. "The customized F.I.T. interface is a further example of Garmin's engineering commitment to providing flexible, frictionless experiences for its users." GRMN - $60.75
0.46 (0.76%) UNH - $211.13
1.27 (0.61%) QCOM - $66.11
0.5 (0.76%) | |
|---|
- $60.75
0.46 (0.76%) - 10/06/17
- NOMU
10/06/17
NO CHANGETarget $275
NOMU
Buy Nomura Instinet lays out potential takeover targets for Broadcom With revenues this year on track to reach $17B, few opportunities in the semiconductor space exist that would move the needle for Broadcom Limited (AVGO), Nomura Instinet analyst Romit Shah tells investors in a research note. As a result, the analyst believes the company could be looking to acquire companies in peripheral spaces. Shah's analysis yields CA Technologies (CA), NetApp (NTAP), Juniper (JNPR), Garmin (GRMN), Trimble (TRMB), Akamai (AKAM), F5 Networks (FFIV), Ciena (CIEN) and EchoStar (SATS) as possible takeover targets. The analyst thinks Broadcom shares may continue to "languish" in the near term given uncertainty with the Brocade acquisition and iPhone supply constraints. Shah, however, remains optimistic in Broadcom's ability to generate $20-plus in earnings per share in the future. He keeps a Buy rating on the shares with a $275 price target. - 07/19/17
- LBOW
Garmin upgraded on 'bullish trends,' valuation, at Longbow As noted earlier, Longbow analyst Joe Wittine upgraded Garmin to Buy from Neutral. He upgraded the stock based on valuation and his belief that the company will be boosted by "bullish trends" in its "Outdoor, Aviation, and Marine segments." Target $60. : - 07/19/17
- LBOW
Garmin upgraded to Buy from Neutral at Longbow - 05/04/17
On The Fly: Top five analyst downgrades Catch up on today's top five analyst downgrades with this list compiled by The Fly: Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Garmin (GRMN) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster citing valuation and less likelihood for upside surprises throughout the remainder of 2017 due to tough comparisons. The analyst lowered his price target for the shares to $50 from $55. 2. Square (SQ) downgraded to Neutral from Buy at Guggenheim with the firm citing valuation and maintained a $20 price target on shares. 3. Tractor Supply (TSCO) downgraded to Perform from Outperform at Oppenheimer with analyst Brian Nagel citing concerns about the company's "modest" earnings growth could drive multiple contraction. The analyst thinks a guidance cut is likely when Tractor reports second quarter results in July. 4. Molson Coors (TAP) downgraded to Hold from Buy at Societe Generale with analyst Andrew Holland saying investments will impact margins. 5. MEDNAX (MD) downgraded two notches to Underperform from Buy at BofA/Merrill with the firm's analyst citing concerns cost pressures and worsening top line trends. The analyst lowered its price target to $57 from $75. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. - $211.13
1.27 (0.61%) - 11/06/17
- OPCO
Tivity Health oversold on UnitedHealth news, says Oppenheimer Oppenheimer analyst Mohan Naidu views Tivity Health (TVTY) as oversold after UnitedHealth (UNH) said its Optum Fitness Advantage program will be available, at no additional cost, to Individual Medicare Advantage plans members in 11 states, starting January 2018. The analyst believes this is only for the individual market and that Tivity's SilverSneakers will be available for all group members. Further, he notes that Tivity management confirmed that their initial 2018 guidance already contemplates the impact of the UnitedHealth rollout. While it is possible that the Optum Fitness introduction is a precursor to a broader program, SilverSneaker's name and trust drives a lot of enrollment decisions and will likely be a deciding factor in the expansion of this new offering, Naidu tells investors in an intraday research note. Tivity Health is down 31%, or $14.70, to $33.35 in afternoon trading. - 11/06/17
- JEFF
Tivity Health should be bought on selloff, says Jefferies Jefferies analyst David Styblo estimates Tivity Health's (TVTY) contract with UnitedHealth (UNH) represents 15% of Tivity's revenue and today's pullback on news of a competitor to Silver Sneakers seems to be pricing in "more than a worst case scenario." He would be a buyer on the selloff. - 11/06/17
- WBLR
11/06/17
NO CHANGEWBLR
Outperform Tivity Health selloff today a buying opportunity, says William Blair William Blair views today's pullback in shares of Tivity Health (TVTY) as overdone and recommends buying the shares at current levels. While the news from UnitedHealth (UNH) represents lost contracts, management has been aware of this since June, the firm tells investors. It notes Tivity successfully extended its contract with UnitedHealth this year. - 11/07/17
- BRRR
11/07/17
NO CHANGETarget $40
BRRR
Outperform Tivity Health price target lowered to $40 from $46 at Barrington Barrington analyst Michael Petusky lowered his price target for Tivity Health (TVTY) to $40 after UnitedHealth (UNH), which represents about 15%-17% of Tivity's overall revenue, disclosed that it would be competing with the company's SilverSneakers program in 11 states as of January 1, 2018. Based on the analyst's conversation last night with management, he still suspects UnitedHealth will continue to be a material customer of Tivity through at least the end of the contract in 2020. Petusky cations, however, that he has no real clarity on how much additional business could transition to United's internal offering beyond 2018. He maintains an Outperform rating on Tivity Health. - $66.11
0.5 (0.76%) - 11/14/17
- NOMU
Qualcomm holders likely compelled by $80 per share offer, says Nomura A takeover offer of $80 per share or higher by Broadcom (AVGO) would be perceived as "highly compelling" to Qualcomm's (QCOM) largest shareholders, Nomura Instinet analyst Romit Shah told investors yesterday in a research note. He believes Broadcom "has a lot of leverage" even though Qualcomm expressed no interest in negotiating yesterday when rejecting Broadcom's $70 per share offer. Broadcom is likely to get more aggressive with its bid for Qualcomm, via either the launch of a public exchange offer for all shares or announcing a slate of directors for nomination, Shah contends. The analyst sees more upside in Broadcom than Qualcomm should a deal get consummated. Broadcom can rally 35% to $360 per share while Qualcomm will likely rally 15%-25% to $75-$80 per share in a deal scenario, the analyst estimates. - 11/13/17
- ADAM
Qualcomm price target raised to $83 at Canaccord after rejecting Broadcom bid Canaccord analyst T. Michael Walkley raised his price target on Qualcomm (QCOM) to $83 from $76 after the company's board unanimously rejected a $70 per share unsolicited bid by Broadcom (AVGO). Walkley maintained a Buy rating on Qualcomm shares, saying 1) he has increased confidence the company can resolve its Qualcomm Technology Licensing issues, and 2) he expects Broadcom to raise its bid for Qualcomm. - 11/08/17
On The Fly: Top five analyst upgrades Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) was upgraded to Outperform from Sector Perform at RBC Capital and to Outperform from Market Perform at Raymond James. 2. Chubb (CB) upgraded to Overweight from Neutral at JPMorgan with analyst Sarah DeWitt saying she believes Chubb will be a "major beneficiary" as investors look to gain exposure to the Property & Casualty Insurance space post the third quarter catastrophe losses. 3. Take-Two (TTWO) upgraded to Outperform from Neutral at Baird with analyst Colin Sebastian citing its faster growth and better operating discipline than he expected and "essentially none" of the Grand Theft Auto usage decay he expected. 4. Hain Celestial (HAIN) upgraded to Outperform from Market Perform at Bernstein. 5. Welltower (HCN) upgraded to Overweight from Equalweight at Capital One. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. - 11/14/17
- RBCM
11/14/17
NO CHANGETarget $77
RBCM
Outperform Qualcomm price target raised to $77 from $70 at RBC Capital RBC Capital analyst Amit Daryanani raised his price target on Qualcomm (QCOM) to $77 after yesterday's formal rejection of $70 per share offer from Broadcom (AVGO). Daryanani says the rejection is not a surprise, noting that the next likely steps are for Broadcom to present its offer to shareholders and escalate the process to a proxy battle that may yield a higher bid. The analyst keeps his Outperform rating on Qualcomm, saying investors will likely agree to the Broadcom deal at a higher price of "high $70's to low $80's". |